The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.

The FDA granted approval for Journavx after clinical trials demonstrated its effectiveness in post-surgical pain relief ...

On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...

The Food and Drug Administration on Tuesday approved Journavx, the first drug in a new class of non-opioid pain medications, ...

The FDA approved Vertex Pharmaceuticals' Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, ...